Trial Outcomes & Findings for A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal (NCT NCT05654662)
NCT ID: NCT05654662
Last Updated: 2025-01-13
Results Overview
The number of bleeding sites was calculated using the bleeding index (BI) assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.
COMPLETED
NA
197 participants
Baseline and Week 12
2025-01-13
Participant Flow
This study was conducted at a single center in the United Kingdom.
A total of 204 participants were screened of which 197 participants were enrolled, and 190 participants were randomized to receive treatment in 2 groups: Test Product group (94 participants) and Reference Product group (96 participants). 14 participants were not randomized (9 participants did not meet study criteria; 2 participants were lost to follow-up; and 3 participants withdrew their consent). A total of 188 randomized participants completed the study.
Participant milestones
| Measure |
Test Product (Corsodyl Original Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67 percent (%) weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Overall Study
STARTED
|
94
|
96
|
|
Overall Study
COMPLETED
|
92
|
96
|
|
Overall Study
NOT COMPLETED
|
2
|
0
|
Reasons for withdrawal
| Measure |
Test Product (Corsodyl Original Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67 percent (%) weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
0
|
|
Overall Study
A death in the family
|
1
|
0
|
Baseline Characteristics
A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal
Baseline characteristics by cohort
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Total
n=190 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
39.2 years
STANDARD_DEVIATION 12.08 • n=99 Participants
|
39.8 years
STANDARD_DEVIATION 13.20 • n=107 Participants
|
39.5 years
STANDARD_DEVIATION 12.63 • n=206 Participants
|
|
Sex: Female, Male
Female
|
69 Participants
n=99 Participants
|
67 Participants
n=107 Participants
|
136 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
25 Participants
n=99 Participants
|
29 Participants
n=107 Participants
|
54 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
94 Participants
n=99 Participants
|
96 Participants
n=107 Participants
|
190 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
African American/African Heritage
|
4 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Asian - Central/South Asian Heritage
|
5 Participants
n=99 Participants
|
10 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Asian - East Asian Heritage
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Asian - South East Asian Heritage
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
White - White/Caucasian/European Heritage
|
73 Participants
n=99 Participants
|
71 Participants
n=107 Participants
|
144 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Multiple
|
10 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline and Week 12Population: mITT Population. Here, overall number analyzed is defined as the number of participants with data available for analysis of this outcome measure.
The number of bleeding sites was calculated using the bleeding index (BI) assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=92 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 12
|
-4.3 bleeding sites
Standard Error 1.44
|
—
|
SECONDARY outcome
Timeframe: Baseline and Week 12Population: mITT Population. Here, overall number analyzed is defined as the number of participants with data available for analysis of this outcome measure.
The number of bleeding sites was calculated using the BI assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=92 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 12 (Test Product Versus [vs.] Reference Product)
|
-4.3 bleeding sites
Standard Error 1.44
|
2.3 bleeding sites
Standard Error 1.42
|
SECONDARY outcome
Timeframe: Baseline, Week 3, and Week 6Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
The number of bleeding sites was calculated using the BI assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 3 and Week 6
Change from Baseline at Week 3
|
-2.4 bleeding sites
Standard Error 1.02
|
—
|
|
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 3 and Week 6
Change from Baseline at Week 6
|
-2.4 bleeding sites
Standard Error 1.26
|
—
|
SECONDARY outcome
Timeframe: Baseline, Week 3, and Week 6Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
The number of bleeding sites was calculated using the BI assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 3 and Week 6 (Test Product vs. Reference Product)
Change from Baseline at Week 3
|
-2.4 bleeding sites
Standard Error 1.02
|
1.4 bleeding sites
Standard Error 1.02
|
|
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 3 and Week 6 (Test Product vs. Reference Product)
Change from Baseline at Week 6
|
-2.4 bleeding sites
Standard Error 1.26
|
2.9 bleeding sites
Standard Error 1.25
|
SECONDARY outcome
Timeframe: Baseline, Weeks 3, 6 and 12Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing and scored on a 3-point scale ranging from 0 to 2, where 0=No bleeding after 30 seconds; 1=Bleeding observed within 30 seconds of probing; 2=Bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated better outcome. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12
Change from Baseline at Week 3
|
-0.04 score on a scale
Standard Error 0.008
|
—
|
|
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12
Change from Baseline at Week 6
|
-0.04 score on a scale
Standard Error 0.009
|
—
|
|
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12
Change from Baseline at Week 12
|
-0.06 score on a scale
Standard Error 0.011
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 3, 6 and 12Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing and scored on a 3-point scale ranging from 0 to 2, where 0=No bleeding after 30 seconds; 1=Bleeding observed within 30 seconds of probing; 2=Bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated better outcome. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 12
|
-0.06 score on a scale
Standard Error 0.011
|
-0.01 score on a scale
Standard Error 0.011
|
|
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 3
|
-0.04 score on a scale
Standard Error 0.008
|
-0.01 score on a scale
Standard Error 0.008
|
|
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 6
|
-0.04 score on a scale
Standard Error 0.009
|
-0.00 score on a scale
Standard Error 0.009
|
SECONDARY outcome
Timeframe: Baseline, Weeks 3, 6 and 12Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
MGI assessment is a non-invasive evaluation which focuses on visual symptoms of gingivitis (example, redness, texture, edema). MGI was assessed for all evaluable surfaces of facial and lingual/palatal gingiva,4 sites per tooth and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation;1=Mild inflammation;slight change in color,little change in color;little change in texture of any portion of marginal or papillary gingival unit;2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit;3=Moderate inflammation;glazing, redness, edema, and/or hypertrophy of marginal or papillary gingival unit;4= Severe inflammation;marked redness, edema and/or hypertrophy of marginal or papillary gingival unit,spontaneous bleeding, congestion, or ulceration. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline \[Day 0\] value. A negative change from Baseline indicated improvement in symptoms.
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Mean Mean Modified Gingival Index (MGI) at Weeks 3, 6 and 12
Change from Baseline at Week 3
|
-0.12 score on a scale
Standard Error 0.014
|
—
|
|
Adjusted Mean Change From Baseline in Mean Mean Modified Gingival Index (MGI) at Weeks 3, 6 and 12
Change from Baseline at Week 6
|
-0.19 score on a scale
Standard Error 0.019
|
—
|
|
Adjusted Mean Change From Baseline in Mean Mean Modified Gingival Index (MGI) at Weeks 3, 6 and 12
Change from Baseline at Week 12
|
-0.24 score on a scale
Standard Error 0.021
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 3, 6 and 12Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
MGI assessment is a non-invasive evaluation which focuses on visual symptoms of gingivitis (example, redness, texture, edema). MGI was assessed for all evaluable surfaces of facial and lingual/palatal gingiva,4 sites per tooth and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation;1=Mild inflammation;slight change in color,little change in color;little change in texture of any portion of marginal or papillary gingival unit;2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit;3=Moderate inflammation;glazing, redness, edema, and/or hypertrophy of marginal or papillary gingival unit;4= Severe inflammation;marked redness, edema and/or hypertrophy of marginal or papillary gingival unit,spontaneous bleeding, congestion, or ulceration. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline \[Day 0\] value. A negative change from Baseline indicated improvement in symptoms.
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Mean MGI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 3
|
-0.12 score on a scale
Standard Error 0.014
|
-0.04 score on a scale
Standard Error 0.014
|
|
Adjusted Mean Change From Baseline in Mean MGI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 6
|
-0.19 score on a scale
Standard Error 0.019
|
-0.06 score on a scale
Standard Error 0.019
|
|
Adjusted Mean Change From Baseline in Mean MGI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 12
|
-0.24 score on a scale
Standard Error 0.021
|
-0.10 score on a scale
Standard Error 0.021
|
SECONDARY outcome
Timeframe: Baseline, Weeks 3, 6 and 12Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (7-7 in each arch). 3 scores were recorded facially(distal, body, mesial sites), and 3 scores were recorded lingually(distal, body, mesial sites). Plaque was first disclosed using a dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 millimeter\[mm\]) at the cervical margin; 3=Band of plaque wider than 1 mm but covering less than (\<)1/3 of the tooth surface; 4=Plaque covering greater than or equal to (\>=)1/3 but \<2/3 of the tooth surface; 5=Plaque covering \>=2/3 of the tooth surface. Mean overall TPI score=Average of TPI values over all tooth sites assessed for a participant. Lower score=better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Mean Overall TPI (Turesky Plaque Index) at Weeks 3, 6 and 12
Change from Baseline at Week 3
|
-0.32 score on a scale
Standard Error 0.033
|
—
|
|
Adjusted Mean Change From Baseline in Mean Overall TPI (Turesky Plaque Index) at Weeks 3, 6 and 12
Change from Baseline at Week 6
|
-0.31 score on a scale
Standard Error 0.043
|
—
|
|
Adjusted Mean Change From Baseline in Mean Overall TPI (Turesky Plaque Index) at Weeks 3, 6 and 12
Change from Baseline at Week 12
|
-0.41 score on a scale
Standard Error 0.047
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 3, 6 and 12Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (7-7 in each arch). 3 scores were recorded facially (distal, body, mesial sites), and 3 scores were recorded lingually (distal, body, mesial sites). Plaque was first disclosed using a dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface; 4=Plaque covering \>=1/3 but \<2/3 of the tooth surface; 5=Plaque covering \>=2/3 of the tooth surface. Mean overall TPI score=Average of TPI values over all tooth sites assessed for a participant. Lower score=better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Mean Overall TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 3
|
-0.32 score on a scale
Standard Error 0.033
|
-0.17 score on a scale
Standard Error 0.033
|
|
Adjusted Mean Change From Baseline in Mean Overall TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 6
|
-0.31 score on a scale
Standard Error 0.043
|
-0.14 score on a scale
Standard Error 0.043
|
|
Adjusted Mean Change From Baseline in Mean Overall TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 12
|
-0.41 score on a scale
Standard Error 0.047
|
-0.12 score on a scale
Standard Error 0.046
|
SECONDARY outcome
Timeframe: Baseline, Weeks 3, 6 and 12Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (7-7 in each arch). 3 scores were recorded facially (distal, mesial sites), and 3 scores were recorded lingually (distal, mesial sites). Plaque was first disclosed using a dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface; 4=Plaque covering \>=1/3 but \<2/3 of the tooth surface; 5=Plaque covering \>=2/3 of the tooth surface. Mean interproximal TPI score=Average of TPI values over distal and mesial tooth sites assessed for a participant. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12
Change from Baseline at Week 6
|
-0.34 score on a scale
Standard Error 0.047
|
—
|
|
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12
Change from Baseline at Week 3
|
-0.35 score on a scale
Standard Error 0.036
|
—
|
|
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12
Change from Baseline at Week 12
|
-0.42 score on a scale
Standard Error 0.052
|
—
|
SECONDARY outcome
Timeframe: Baseline, Weeks 3, 6 and 12Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.
TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (7-7 in each arch). 3 scores were recorded facially (distal, mesial sites), and 3 scores were recorded lingually (distal, mesial sites). Plaque was first disclosed using a dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface; 4=Plaque covering \>=1/3 but \<2/3 of the tooth surface; 5=Plaque covering \>=2/3 of the tooth surface. Mean interproximal TPI score=Average of TPI values over distal and mesial tooth sites assessed for a participant. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).
Outcome measures
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 3
|
-0.35 score on a scale
Standard Error 0.036
|
-0.19 score on a scale
Standard Error 0.036
|
|
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 6
|
-0.34 score on a scale
Standard Error 0.047
|
-0.17 score on a scale
Standard Error 0.047
|
|
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 12
|
-0.42 score on a scale
Standard Error 0.052
|
-0.12 score on a scale
Standard Error 0.052
|
Adverse Events
Test Product (Corsodyl Original Toothpaste)
Reference Product (Colgate Cavity Protection Toothpaste)
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Test Product (Corsodyl Original Toothpaste)
n=94 participants at risk
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 participants at risk
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
|
|---|---|---|
|
Gastrointestinal disorders
GINGIVAL BLEEDING
|
0.00%
0/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
1.0%
1/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
TOOTHACHE
|
0.00%
0/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
1.0%
1/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
|
Gastrointestinal disorders
VOMITING
|
0.00%
0/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
1.0%
1/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
|
Injury, poisoning and procedural complications
GINGIVAL INJURY
|
2.1%
2/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
0.00%
0/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
|
Nervous system disorders
MIGRAINE
|
0.00%
0/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
1.0%
1/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER